BACKGROUND: Problems related to the central nervous system may have major impact on morbidity and mortality. The aim of this retrospective study was to evaluate the nature and incidence of serious neurologic events in patients following liver transplantation. METHODS: Between January 2001 and May 2004, 168 patients (105 female, 63 male) requiring transplantation for alcoholic cirrhosis, hepatitis B and C, and acute liver failure were admitted to the Intensive Care Unit (ICU) of University Hospital Essen after liver transplantation. We identified the reason for the neurologic events, the underlying disease, type of immunosuppression, and the survival rate. RESULTS: Severe neurologic events occurred in 46 (27.3%) of the patients. The length of stay of these patients in the ICU (18.4 +/- 19.7 days) was longer in comparison to the total patients (8.3 +/- 9.5 days, p < 0.05). The most common neurological complications were encephalopathy (18.5%) and seizures (5.4%). The survival rate after liver transplantation with neurological events was lower compared to patients without, but not significantly different (73.9 vs. 79.5%). The calcineurin inhibitor used had no impact on neurological events [cyclosporine (25.5%); tacrolimus (32.5%)]. CONCLUSIONS: There was a high incidence of serious neurologic events after liver transplantation. The major neurologic manifestation in our patients was encephalopathy followed by seizures.
BACKGROUND: Problems related to the central nervous system may have major impact on morbidity and mortality. The aim of this retrospective study was to evaluate the nature and incidence of serious neurologic events in patients following liver transplantation. METHODS: Between January 2001 and May 2004, 168 patients (105 female, 63 male) requiring transplantation for alcoholic cirrhosis, hepatitis B and C, and acute liver failure were admitted to the Intensive Care Unit (ICU) of University Hospital Essen after liver transplantation. We identified the reason for the neurologic events, the underlying disease, type of immunosuppression, and the survival rate. RESULTS: Severe neurologic events occurred in 46 (27.3%) of the patients. The length of stay of these patients in the ICU (18.4 +/- 19.7 days) was longer in comparison to the total patients (8.3 +/- 9.5 days, p < 0.05). The most common neurological complications were encephalopathy (18.5%) and seizures (5.4%). The survival rate after liver transplantation with neurological events was lower compared to patients without, but not significantly different (73.9 vs. 79.5%). The calcineurin inhibitor used had no impact on neurological events [cyclosporine (25.5%); tacrolimus (32.5%)]. CONCLUSIONS: There was a high incidence of serious neurologic events after liver transplantation. The major neurologic manifestation in our patients was encephalopathy followed by seizures.
Authors: Fuat H Saner; Silvio Nadalin; Arnold Radtke; Georgios C Sotiropoulos; Gernot M Kaiser; Andreas Paul Journal: Metab Brain Dis Date: 2009-01-13 Impact factor: 3.584
Authors: Katherine A Fu; Joseph DiNorcia; Linda Sher; Shamsha A Velani; Shahrzad Akhtar; Laura A Kalayjian; Nerses Sanossian Journal: Front Neurol Date: 2014-12-17 Impact factor: 4.003
Authors: Adam S Vesole; Yasunori Nagahama; Mark A Granner; Matthew A Howard; Hiroto Kawasaki; Brian J Dlouhy Journal: Epilepsy Behav Case Rep Date: 2018-02-08
Authors: Henning Pflugrad; Anita Blanka Tryc; Annemarie Goldbecker; Hannelore Barg-Hock; Christian Strassburg; Jürgen Klempnauer; Heinrich Lanfermann; Karin Weissenborn; Peter Raab Journal: PLoS One Date: 2019-08-23 Impact factor: 3.240
Authors: Yao Li; Haijiu Wang; Dongdong Han; Zhixin Wang; Li Zhang; Shiwei Yang; Qiang Wang; Hao Wen; Haining Fan Journal: J Int Med Res Date: 2019-11-10 Impact factor: 1.671
Authors: Fuat Hakan Saner; Julia Gensicke; Steven W M Olde Damink; Goran Pavlaković; Juergen Treckmann; Marc Dammann; Gernot M Kaiser; Georgios C Sotiropoulos; Arnold Radtke; Susanne Koeppen; Susanne Beckebaum; Vito Cicinnati; Silvio Nadalin; Massimo Malagó; Andreas Paul; Christoph E Broelsch Journal: J Neurol Date: 2009-09-01 Impact factor: 4.849